Skip to main content

Advertisement

Table 7 Details of adverse events of nintedanib in the switch and pirfenidone-naïve groups

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  Switch-group (n = 30) Pirfenidone-naïve group (n = 64)
Subjects CTCAE grade Subjects CTCAE grade
1 2 3 1 2 3
Gastrointestinal
 Anorexia 14 (46.7%) 3 8 3 14 (21.9%) 8 2 4
 Diarrhea 14 (46.7%) 6 7 1 34 (53.1%) 20 10 4
 Weight loss 6 (20.0%) 3 3 0 6 (9.3%) 2 3 1
 Nausea 2 (6.7%) 0 2 0 11 (17.1%) 5 5 1
 Vomiting 2 (6.7%) 2 0 0 3 (4.7%) 3 0 0
 Dyspepsia 0 0 0 0 1 (1.6%) 0 1 0
Other
 AST/ALT elevation 19 (63.3%) 12 5 2 46 (71.9%) 28 12 6
 Fatigue 3 (10.0%) 1 1 1 5 (7.8%) 2 3 0
 Abdominal pain 3 (10.0%) 2 1 0 3 (4.7%) 3 0 0
 Fever 2 (6.7%) 2 0 0 4 (6.3%) 4 0 0
 Acute exacerbation 2 (6.7%) 3 (4.7%)
 Pneumothorax 0 3 (4.7%)
 Rash 0 0 0 0 2 (3.1%) 0 2 0
 Hemoptysis 0 1 (1.6%)
 Cerebral infarction 0 1 (1.6%)
 Eosinophilia 0 1 (1.6%)
 Pneumatosis intestinalis 0 1 (1.6%)
 Hematochezia 0 1 (1.6%)
 Thrombocytopenia 0 1 (1.6%) 1 0 0
  1. Categorical data are presented as numbers (percentages)
  2. Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase, CTCAE Common Terminology Criteria for Adverse Events